5/28
12:18 pm
ipsey
Annual General Meeting of Ipsen S.A. held on 28 May 2024 [Yahoo! Finance]
Neutral
Report
Annual General Meeting of Ipsen S.A. held on 28 May 2024 [Yahoo! Finance]
5/2
01:30 am
ipsey
Ipsen appoints Keira Driansky as EVP, President of North America
Neutral
Report
Ipsen appoints Keira Driansky as EVP, President of North America
4/24
01:00 am
ipsey
Ipsen delivers strong sales in the first quarter of 2024, driven by growth platforms & new medicines, and confirms its full-year guidance
Low
Report
Ipsen delivers strong sales in the first quarter of 2024, driven by growth platforms & new medicines, and confirms its full-year guidance
4/23
05:28 pm
ipsey
Ipsen en Skyhawk Therapeutics kondigen samenwerking aan op het gebied van onderzoek naar RNA-targeting bij zeldzame neurologische aandoeningen
Low
Report
Ipsen en Skyhawk Therapeutics kondigen samenwerking aan op het gebied van onderzoek naar RNA-targeting bij zeldzame neurologische aandoeningen
4/22
01:00 am
ipsey
Ipsen and Skyhawk Therapeutics announce RNA targeting research collaboration in rare neurological diseases
Medium
Report
Ipsen and Skyhawk Therapeutics announce RNA targeting research collaboration in rare neurological diseases
4/22
01:00 am
ipsey
Ipsen and Skyhawk Therapeutics announce RNA targeting research collaboration in rare neurological diseases
Medium
Report
Ipsen and Skyhawk Therapeutics announce RNA targeting research collaboration in rare neurological diseases
4/22
01:00 am
ipsey
Ipsen and Skyhawk Therapeutics announce RNA targeting research collaboration in rare neurological diseases
Medium
Report
Ipsen and Skyhawk Therapeutics announce RNA targeting research collaboration in rare neurological diseases
4/2
07:00 am
ipsey
Marengo Therapeutics Announces First Drug Candidate Nomination from Oncology Collaboration with Ipsen
Medium
Report
Marengo Therapeutics Announces First Drug Candidate Nomination from Oncology Collaboration with Ipsen
4/2
01:00 am
ipsey
Ipsen and Sutro Biopharma announce exclusive global licensing agreement for an ADC targeting solid tumors
Medium
Report
Ipsen and Sutro Biopharma announce exclusive global licensing agreement for an ADC targeting solid tumors